Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sclerosing cholangitis.

Einar Björnsson1, Roger W Chapman

  • 1Department of Internal Medicine, Section of Gastroenterology and Hepatology, Sahlgrenska University Hospital, Gothenburg, Sweden. einar.bjornsson@medic.gu.se

Current Opinion in Gastroenterology
|February 11, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Determining the time to cholangiocarcinoma in pediatric-onset PSC-IBD.

Journal of pediatric gastroenterology and nutrition·2024
Same author

Dye-based chromoendoscopy detects more neoplasia than white light endoscopy in patients with primary sclerosing cholangitis and IBD.

Endoscopy international open·2024
Same author

Efficacy and safety of infliximab in patients with autoimmune hepatitis.

Hepatology (Baltimore, Md.)·2024
Same author

Primary sclerosing cholangitis-A long night's journey into day.

Clinical liver disease·2022
Same author

N-Acetylcysteine for the Management of Non-Acetaminophen Drug-Induced Liver Injury in Adults: A Systematic Review.

Frontiers in pharmacology·2022
Same author

A retrospective analysis of the duration of mechanical ventilation in Scandinavian paediatric heart centres.

Acta paediatrica (Oslo, Norway : 1992)·2022
Same journal

Endoscopic techniques to minimize gastroesophageal reflux during peroral endoscopic myotomy.

Current opinion in gastroenterology·2026
Same journal

Postendoscopy esophageal adenocarcinoma and neoplasia: current status and future directions.

Current opinion in gastroenterology·2026
Same journal

The complement system in inflammatory bowel disease: from early observations to emerging frontiers.

Current opinion in gastroenterology·2026
Same journal

Goblet cell-associated antigen passages in health and disease.

Current opinion in gastroenterology·2026
Same journal

Inflammatory bowel diseases 2026: form, function and therapeutic considerations for the epithelial barrier.

Current opinion in gastroenterology·2026
Same journal

Dietary protein as a regulator of colitis and colorectal cancer.

Current opinion in gastroenterology·2026
See all related articles

Primary sclerosing cholangitis (PSC) is a chronic liver disease with improved survival rates in recent years. Small duct PSC shows a better prognosis and does not develop cholangiocarcinoma, unlike large duct PSC.

Area of Science:

  • Hepatology
  • Gastroenterology
  • Immunology

Background:

  • Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease affecting the biliary tree.
  • Recent data indicates improved median survival for PSC patients diagnosed in the last decade (18 years vs. 12 years).
  • Small duct PSC is considered a distinct entity with a better prognosis and no progression to cholangiocarcinoma.

Purpose of the Study:

  • To review the current understanding of Primary Sclerosing Cholangitis (PSC).
  • To discuss the prognostic differences between small duct and large duct PSC.
  • To highlight the diagnostic challenges and the need for improved detection of cholangiocarcinoma in PSC patients.

Main Methods:

  • Review of recent literature on Primary Sclerosing Cholangitis.

Related Experiment Videos

  • Analysis of survival data and disease progression in PSC subtypes.
  • Evaluation of diagnostic imaging modalities like MR cholangiopancreatography (MRCP) and ERCP.

    • Main Results:

    • Patients diagnosed with PSC in the last decade have a median survival of 18 years.
    • Small duct PSC rarely progresses to large duct PSC and shows a significantly better prognosis.
    • Cholangiocarcinoma has not been observed in patients with small duct PSC.
    • Autoantibodies targeting biliary epithelial cells are present in PSC, but their pathogenic role is undetermined.
    • MR cholangiopancreatography (MRCP) shows comparable accuracy to ERCP, but standardization is lacking.

    Conclusions:

    • Primary sclerosing cholangitis prognosis has improved, particularly for small duct PSC.
    • Early and accurate diagnosis of cholangiocarcinoma in PSC patients remains a critical unmet need.
    • Further research is needed to clarify the role of autoantibodies and standardize MRCP for PSC diagnosis.